HomeCompareSZIHF vs ABBV

SZIHF vs ABBV: Dividend Comparison 2026

SZIHF yields 8.52% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $81.2K in total portfolio value
10 years
SZIHF
SZIHF
● Live price
8.52%
Share price
$0.90
Annual div
$0.08
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.2K
Annual income
$0.90
Full SZIHF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SZIHF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSZIHFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SZIHF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SZIHF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SZIHF
Annual income on $10K today (after 15% tax)
$724.21/yr
After 10yr DRIP, annual income (after tax)
$0.77/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,055.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SZIHF + ABBV for your $10,000?

SZIHF: 50%ABBV: 50%
100% ABBV50/50100% SZIHF
Portfolio after 10yr
$61.8K
Annual income
$12,386.33/yr
Blended yield
20.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SZIHF
No analyst data
Altman Z
0.5
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SZIHF buys
0
ABBV buys
0
No recent congressional trades found for SZIHF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSZIHFABBV
Forward yield8.52%3.06%
Annual dividend / share$0.08$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$21.2K$102.3K
Annual income after 10y$0.90$24,771.77
Total dividends collected$873.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SZIHF vs ABBV ($10,000, DRIP)

YearSZIHF PortfolioSZIHF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,126$426.01$11,550$430.00$424.00ABBV
2$12,126$221.48$13,472$627.96$1.3KABBV
3$13,088$112.80$15,906$926.08$2.8KABBV
4$14,061$56.89$19,071$1,382.55$5.0KABBV
5$15,074$28.56$23,302$2,095.81$8.2KABBV
6$16,143$14.31$29,150$3,237.93$13.0KABBV
7$17,281$7.16$37,536$5,121.41$20.3KABBV
8$18,494$3.58$50,079$8,338.38$31.6KABBV
9$19,790$1.79$69,753$14,065.80$50.0KABBV
10$21,176$0.90$102,337$24,771.77$81.2KABBV

SZIHF vs ABBV: Complete Analysis 2026

SZIHFStock

Shenzhen International Holdings Limited, an investment holding company, invests in, constructs, and operates logistic infrastructure facilities primarily in the People's Republic of China. It operates through two segments, Toll roads and General Environmental Protection Business, and Logistic Business. The Toll roads and General Environmental Protection Business segment develops, operates, and manages toll highways. This segment also engages in the sale of wind turbine equipment; kitchen waste disposal projects construction; and operation and sale of wind power stations. The company's Logistic Business segment constructs, operates, and manages logistics parks and centers, and integrated logistics hubs; and provides third-party logistics services, logistic information services, and financial services; port and related services; and logistic park transformation and upgrading services. It also operates two general bulk cargo terminals and depots in Nanjing Xiba Port that provides various services, such as loading and unloading, lightering, train loading and unloading, and warehousing. In addition, the company provides electronic information exchange, transmission, and value-added information sharing services; supply chain management services; project investment and enterprise management consulting services; and real estate development and investment management services, as well as operates Longda and Shenzhen Expressway in Shenzhen. Further, it offers logistics and transportation ancillary services, and cargo transportation and warehousing services. Additionally, it provides technical development, sales, maintenance, and technology service of computer hardware, software, and network systems; and monetary and financial leasing, property leasing and management, freight forwarding, and other services. The company is headquartered in Tsimshatsui East, Hong Kong.

Full SZIHF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SZIHF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SZIHF vs SCHDSZIHF vs JEPISZIHF vs OSZIHF vs KOSZIHF vs MAINSZIHF vs JNJSZIHF vs MRKSZIHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.